Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

NCT00780416 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: MP-424
DRUG: Ribavirin
DRUG: Peginterferon Alfa-2b
DRUG: Ribavirin
DRUG: Peginterferon Alfa-2b

Sponsor

Tanabe Pharma Corporation

Collaborators

[object Object]